Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of SGE 102 in patients with refractory status epilepticus

Trial Profile

Phase II trial of SGE 102 in patients with refractory status epilepticus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Brexanolone (Primary) ; Midazolam
  • Indications Status epilepticus
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2016 According to Sage Therapeutics media release, data presented at the. 68th American Academy of Neurology (AAN).
    • 09 Jan 2015 Interim results in 9 evaluable patients published in a SAGE Therapeutics media release.
    • 03 Nov 2014 Results in two paediatric patients published in a Sage Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top